

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016
Email: shreeganeshbiotechindia@gmail.com Website: www.shreeganeshbiotech.com

Date: 13.02.2024

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai – 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir / Madam,

Sub: Un-Audited Financial Result quarter ended on 31st December 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company met in their meeting held on today i.e. **Tuesday 13th February 2024.**

1.) Considered and approved Un-audited financial results for the quarter ended as on 31st December 2023.

The meeting commenced at 04:00 P.M. and concluded at 04:30.P.M.

Kindly take the same on your record and oblige.

Thanking You

Yours faithfully
For SHREE GANESH BIO-TECH (INDIA) LIMITED



Aman P
Wholetime Director
DIN: 08483544

Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email : shreeganeshbiotechindia@gmail.com

Statement of Standalone Financial Results for the quarter ended on December 31, 2023

(₹ In Lakh except per share data)

Particulars	Quarter Ended			Nine Months Ended		Year Ended	
	31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023	
A	Date of start of reporting period						01-10-2022
B	Date of end of reporting period						31-03-2023
C	Whether results are audited or unaudited						Audited
D	Nature of report standalone or consolidated						Standalone
I	Revenue From Operations						
	Net sales or Revenue from Operations	412.25	411.81	1,207.30	1,649.44	5,447.70	6,245.45
II	Other Income	-	-	0.10	-	(1.94)	56.49
III	Total Income (I+II)	412.25	411.81	1,207.40	1,649.44	5,445.76	6,301.94
IV	Expenses						
(a)	Cost of materials consumed	397.50	397.07	1,174.60	1,590.41	5,153.04	5,962.93
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	3.18	3.93	3.83	10.71	15.68	21.77
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and amortisation expense	-	-	-	-	-	0.06
(g)	Other Expenses	2.89	3.29	2.04	17.18	15.26	45.76
	Total expenses (IV)	403.56	404.29	1,180.47	1,618.30	5,183.98	6,030.52
V	Profit/(loss) before exceptional items and tax (III-IV)	8.69	7.52	26.93	31.14	261.78	271.42
VI	Exceptional items	-	-	-	-	-	-
VII	Profit (loss) after exceptional items and before Tax (V-VI)	8.69	7.52	26.93	31.14	261.78	271.42
VIII	Tax Expense						
(a)	Current Tax	-	-	-	-	-	67.55
(b)	(Less):- MAT Credit	-	-	-	-	-	-
(c)	Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(d)	Deferred Tax (Asset)/Liabilities	-	-	-	-	-	-
IX	Profit (Loss) after Tax for the period (VII-VIII)	8.69	7.52	26.93	31.14	261.78	203.87
X	Other Comprehensive Income						
a. i).	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
ii).	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
b. i).	Item that will be reclassified to profit or loss	-	-	-	-	-	-
ii).	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive income	-	-	-	-	-	-
XI	Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)	8.69	7.52	26.93	31.14	261.78	203.87
XII	Details of equity share capital						
	Paid-up equity share capital	3,986.24	3,986.24	3,986.24	3,986.24	3,986.24	3,986.24
	Face value of equity share capital (Per Share)	1.00	1.00	1.00	1.00	1.00	1.00
XIII	Other Equity	-	-	-	-	-	2,249.43
XIV	Earnings per share						
(a)	Earnings per share (not annualised for quarter ended)						
	Basic earnings (loss) per share from continuing operation	0.00	0.00	0.01	0.01	0.07	0.05
	Diluted earnings (loss) per share from continuing operation	0.00	0.00	0.01	0.01	0.07	0.05



Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email : shreeganeshbiotechindiaLtd@gmail.com

Notes on Financial Results:-

1	The above unaudited standalone financial results for the quarter ended December 31, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on February 13, 2024. The statutory auditors have carried out limited review of above result.
2	The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
3	As per Indian Accounting Standard 108 on 'Operating Segment' (Ind AS 108), the company has only one reportable segment.
4	The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
5	Earning Per Share (EPS) for current and previous periods are recalculated, as per the new Face Value of Rs. 1/- per share, consequent to the sub-division of Equity Shares.
6	Provision for Taxation if any will be made at year end.

For, Shree Ganesh Biotech (India) Limited

Date :- 13th February, 2024
Place:- Kolkata


Aman Patel
Wholetime Director
DIN: 08483544



Limited Review Report

To
The Board of Directors of
SHREE GANESH BIO-TECH (INDIA) LIMITED
KOLKATA


We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SHREE GANESH BIO-TECH (INDIA) LIMITED** ("the Company"), for the Quarter ended on December 31, 2023 and year to date result for the period from 01 April, 2023 to 31 December, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W


CA Amit Shah
Partner
M. No. 126337
UDIN: 24126337BKCXQA9171
Place: Vadodara
Date: 13.02.2024

